Popular Inc. logo

Popular Inc. (BPOP)

Delisted
5 Aug 2026
NASDAQ (NGS) NASDAQ (NGS)
$
177. 52
+1.73
+0.9841%
$
11.18B Market Cap
11 P/E Ratio
2.48% Div Yield
450,075 Volume
8.6 Eps
$ 175.79
Previous Close
Day Range
175.71 178.13
Year Range
108.74 179
Want to track BPOP and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
2 Popular AI Stocks to Sell Before They Fall 65% and 73%, According to Certain Wall Street Analysts

2 Popular AI Stocks to Sell Before They Fall 65% and 73%, According to Certain Wall Street Analysts

Palantir Technologies (PLTR 23.99%) and Tesla (TSLA 2.22%) were two of the most popular stocks among retail investors last year as measured by net inflows. But most Wall Street analysts expect both stocks to decline this year.

Fool | 1 year ago
Can This Popular Vanguard Tech ETF Trounce the S&P 500 Again in 2025?

Can This Popular Vanguard Tech ETF Trounce the S&P 500 Again in 2025?

Exchange-traded funds (ETFs) have transformed the investing landscape since their 1993 debut, attracting investors with their straightforward approach to diversification. By allowing individuals to buy shares that track entire market indexes or sectors, ETFs eliminate the challenge and risk of selecting individual stocks while keeping costs minimal.

Fool | 1 year ago
Popular Q4 Earnings & Revenues Beat on Higher NII, Provisions Fall Y/Y

Popular Q4 Earnings & Revenues Beat on Higher NII, Provisions Fall Y/Y

A rise in NII, along with higher loan and deposit balances, aids BPOP's Q4 earnings. Yet, a rise in costs and a fall in fee income are headwinds.

Zacks | 1 year ago
Popular, Inc. (BPOP) Q4 2024 Earnings Conference Call Transcript

Popular, Inc. (BPOP) Q4 2024 Earnings Conference Call Transcript

Popular, Inc. (BPOP) Q4 2024 Earnings Conference Call Transcript

Seekingalpha | 1 year ago
Ozempic Approved By FDA For Kidney Disease—In Ultra-Popular Drug's Latest Approval

Ozempic Approved By FDA For Kidney Disease—In Ultra-Popular Drug's Latest Approval

The Food and Drug Administration approved Ozempic for treating patients with chronic kidney disease on Tuesday, marking the latest authorized use for Novo Nordisk's popular drug known for diabetes and weight loss.

Forbes | 1 year ago
Popular (BPOP) Q4 Earnings and Revenues Surpass Estimates

Popular (BPOP) Q4 Earnings and Revenues Surpass Estimates

Popular (BPOP) came out with quarterly earnings of $2.51 per share, beating the Zacks Consensus Estimate of $2.04 per share. This compares to earnings of $1.94 per share a year ago.

Zacks | 1 year ago
2 Popular Quantum Computing Stocks Could Drop 52% and 77%, According to Wall Street

2 Popular Quantum Computing Stocks Could Drop 52% and 77%, According to Wall Street

Alphabet subsidiary Google recently announced two major technical achievements with its Willow quantum computing chip. In response to the news, shares of Rigetti Computing (RGTI -3.16%) and D-Wave Quantum (QBTS -3.52%) during the next three weeks advanced 280% and 110%, respectively.

Fool | 1 year ago
Popular (BPOP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Popular (BPOP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Popular (BPOP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks | 1 year ago
1 Popular Cryptocurrency With 13,031% Upside, According to MicroStrategy's Michael Saylor

1 Popular Cryptocurrency With 13,031% Upside, According to MicroStrategy's Michael Saylor

The total value of all cryptocurrencies in circulation currently stands at $3.5 trillion, which is near a record high. Bitcoin (BTC 1.25%) accounts for more than half of that value, thanks to its market capitalization of almost $2 trillion.

Fool | 1 year ago
2 Popular AI Stocks to Sell Before They Drop 24% and 66% in 2025, According to Certain Wall Street Analysts

2 Popular AI Stocks to Sell Before They Drop 24% and 66% in 2025, According to Certain Wall Street Analysts

Apple (AAPL -2.41%) shares have advanced 34% during the past year, but that upside has been driven almost entirely by valuation multiple expansion rather than earnings growth. Consequently, some Wall Street analysts have turned bearish on the stock in the last couple of weeks.

Fool | 1 year ago
One Popular Dividend Stock To Sell And One Strong Buy

One Popular Dividend Stock To Sell And One Strong Buy

The recent market rally has been very uneven. Some stocks surged, while others were left behind. There are great opportunities among dividend stocks. I highlight one of my largest holdings going into 2025.

Seekingalpha | 1 year ago
2 Popular AI Stocks to Sell Before They Fall 55% and 68% in 2025, According to Certain Wall Street Analysts

2 Popular AI Stocks to Sell Before They Fall 55% and 68% in 2025, According to Certain Wall Street Analysts

Shares of Palantir Technologies (PLTR -7.81%) advanced 1,110% during the last two years as the company benefited from strong demand for its artificial intelligence platform. But most Wall Street analysts see the stock as wildly overvalued.

Fool | 1 year ago
Loading...
Load More